Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and is expanding its neuropsychiatry business, particularly with Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy emphasizes the growth of its commercial portfolio, with Jornay PM as the primary growth driver, and aims to deploy capital in a disciplined manner [3].

Core Points - Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary as a publicly traded company by ringing the Nasdaq opening bell on October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD, which is now the fastest growing stimulant medicine for ADHD [2] - Collegium's strategy focuses on growing its commercial portfolio, with Jornay PM as the primary growth driver, while maintaining a disciplined approach to capital deployment [3] Company Overview - Collegium is a diversified biopharmaceutical company dedicated to improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company is headquartered in Stoughton, Massachusetts, and aims to continue making a positive impact in the healthcare community [3]

Core Insights - Collegium Pharmaceutical, Inc. is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market, with a bell-ringing ceremony scheduled for October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM® for ADHD, which is now the fastest growing stimulant medicine for ADHD treatment [2][3] Company Overview - Collegium is focused on building a diversified biopharmaceutical company aimed at improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company's strategy includes expanding its commercial portfolio, with Jornay PM as the primary growth driver, and managing capital deployment in a disciplined manner [3]

Core Viewpoint - Collegium Pharmaceutical, Inc. has authorized a new share repurchase program to buy back up to $150 million in common stock, replacing a previous program that had $65 million remaining [1][2]. Financial Position and Strategy - The company emphasizes its strong financial position, which allows for flexibility in capital allocation and supports shareholder value return [2]. - Since 2021, Collegium has returned $222 million to shareholders through share repurchase programs, including $25 million from an accelerated program initiated in May 2025 [2]. Share Repurchase Program Details - The new share repurchase program is set to run through December 31, 2026, and replaces a previous program that expired on June 30, 2025 [1]. - As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding [3]. Company Overview - Collegium is focused on improving the lives of individuals with serious medical conditions and has a portfolio that includes pain management medications and the recently acquired Jornay PM® for ADHD [4]. - The company's strategy involves growing its commercial portfolio with Jornay PM as a key growth driver and disciplined capital deployment [4].

Financial Performance and Guidance - Collegium reported 2024 sales of $631 million and expects 2025 sales to reach $743 million, representing an +18% increase[16] - The company anticipates 2025 net product revenues in the range of $735 million to $750 million, reflecting an +18% year-over-year growth[22] - Adjusted EBITDA for 2025 is projected to be between $435 million and $450 million, a +10% increase[22] - Adjusted operating expenses for 2025 are expected to be in the range of $220 million to $230 million, a +49% increase[22] Product Portfolio and Market Position - Jornay PM net revenue is expected to exceed $135 million in 2025, representing a +>34% increase from $100.7 million in 2024[40] - The pain portfolio experienced a +5% revenue growth in 2024, while total revenue grew +11%[20] - Q1 2025 pain portfolio product revenues reached $177.8 million, a +23% increase compared to $144.9 million in Q1 2024[32] - Jornay PM prescriptions grew +24% year-over-year in Q1 2025[32] Capital Allocation and Shareholder Value - Collegium initiated a $25 million Accelerated Share Repurchase (ASR) program in May 2025[33] - The company repurchased $222 million worth of shares between 2021 and 2025[47] Debt and Cash Flow - The company had approximately $200 million in cash and marketable securities at the end of Q1 2025[27] - Net debt to adjusted EBITDA stood at approximately 1.5x at the end of Q1 2025[33]

Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].

Q1 2025 Earnings Report May 8, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events ...

Financial Performance - Collegium Pharmaceutical reported Q1 2025 net revenue of $177.8 million, representing a 23% increase year-over-year from $144.9 million in Q1 2024 [9][24] - The company generated $149.2 million from its pain portfolio, up 3% year-over-year, with all three core products showing revenue growth [10][24] - Net revenue from Jornay PM reached $28.5 million in Q1 2025, with a year-over-year prescription growth of 24% [6][9] Strategic Initiatives - The company completed an expansion of its Jornay PM field force, adding 55 new sales representatives, bringing the total to approximately 180 [3][6] - Collegium reaffirmed its full-year 2025 guidance, projecting product revenues between $735 million and $750 million [8] - The board authorized a $25 million accelerated share repurchase program to enhance shareholder value [3][10] Cash Position and Debt Management - As of the end of Q1 2025, Collegium had cash, cash equivalents, and marketable securities totaling $197.8 million, an increase from $162.8 million at the end of 2024 [3][26] - The company paid down an additional $16.1 million in debt during the quarter [3][10] Leadership and Corporate Updates - Collegium made significant additions to its leadership team and board of directors, including the appointment of new executive leaders and board members [10][10] - The company was recognized as a Top Workplace by USA TODAY and a Best Places to Work honoree by the Boston Business Journal [10][10]